Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyberonics, Inc.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
To enhance the healing process following tooth loss and produce better outcomes after subsequent bone grafts, SweetBio Inc. has developed a dissolvable membrane that contains a small amount of medical-grade Manuka honey. This honey comes from New Zealand and contains the compound MgO, which has been found to have wound healing, antimicrobial and antibacterial properties.
Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.
- Other Names / Subsidiaries